Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility

PR Newswire April 3, 2023

Delcath Systems Announces Closing of Private Placement of up to $85 Million

PR Newswire March 29, 2023

Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

PR Newswire March 27, 2023

Delcath Systems Announces up to $85 Million Financing

PR Newswire March 27, 2023

Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023

PR Newswire March 27, 2023

Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch

PR Newswire February 16, 2023

Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit

PR Newswire February 14, 2023

Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16

PR Newswire January 30, 2023

Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology

PR Newswire January 17, 2023

Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)

PR Newswire December 16, 2022

Delcath Systems Closes Private Placement of $6.2 Million

PR Newswire December 13, 2022

Delcath Systems Announces Private Placement of $6.2 Million

PR Newswire December 8, 2022

Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

PR Newswire December 5, 2022

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire November 9, 2022

Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update

PR Newswire November 8, 2022

Delcath Systems to Host Third Quarter 2022 Results

PR Newswire October 24, 2022

Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022

PR Newswire September 1, 2022

Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update

PR Newswire August 8, 2022

Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

PR Newswire August 5, 2022

Delcath Systems to Host Second Quarter 2022 Results

PR Newswire July 27, 2022